UseCases_ArguminSci_Discourse  

PubMed:11850540 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-202 DRI_Background denotes Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
T2 203-383 DRI_Background denotes Amplification of Her-2/neu in breast carcinoma is associated with poor prognosis, short disease-free interval, and short survival time in both node-negative and -positive patients.
T3 384-517 DRI_Challenge denotes Little is known about the starting point of amplification of Her-2/neu and how it progresses from benign to malignant breast lesions.
T4 518-694 DRI_Approach denotes We attempted to address these questions by evaluating amplification of Her-2/neu in benign, premalignant, and malignant lesions using fluorescence in situ hybridization (FISH).
T5 695-1152 DRI_Background denotes Twenty-six patients with Her-2/neu-overexpressing invasive ductal carcinomas (as judged by strong immunoreactivity with Her-2/neu antibody) and coexisting lesions of ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) in the vicinity of the invasive tumor (as judged by review of the hematoxylin and eosin-stained sections), as well as metastatic carcinoma in axillary lymph nodes (mets) were selected for this study.
T6 1153-1338 DRI_Background denotes In the primary carcinomas, a close relationship was present between overexpression as detected by immunohistochemistry (IHC) and amplification as demonstrated by FISH (85% concordance).
T7 1339-1480 DRI_Background denotes Among these patients, amplification of Her-2/neu in ADH was demonstrated in 7 of 13 cases with ADH, and in DCIS, in 21 of 22 cases with DCIS.
T8 1481-1542 DRI_Background denotes There was no amplification in DH or normal ductal epithelium.
T9 1543-1713 DRI_Outcome denotes Significantly, in all 12 patients with synchronous positive axillary lymph nodes, there was concordant amplification of Her-2/neu in the primary and metastatic carcinoma.
T10 1714-1822 DRI_Outcome denotes Amplification was consistent in multifocal metastases, despite morphological heterogeneity in some patients.
T11 1823-2078 DRI_Outcome denotes Amplification ratios increased from ADH to DCIS to invasive carcinoma (P <.01, ADH versus DCIS; P <.05, DCIS versus invasive cancer), but there was no difference in amplification ratios between primary cancers and synchronous axillary metastases (P >.05).
T12 2079-2260 DRI_Approach denotes We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody).
T13 2261-2377 DRI_Outcome denotes Three showed amplification in both primary and metastatic lesions, with a low amplification ratio (approximately 2).
T14 2378-2463 DRI_Outcome denotes One patient had amplification in the primary tumor but not in an axillary metastasis.
T15 2464-2589 DRI_Background denotes Two patients exhibited slight amplification in the metastatic carcinoma (ratios 1.6 and 2), but not in their primary cancers.
T16 2590-2780 DRI_Outcome denotes This FISH study indicates that amplification of Her-2/neu can emerge de novo in any stage of the disease process, from ADH to metastatic lesions, but most often appears first in ADH or DCIS.
T17 2781-2927 DRI_Outcome denotes The degree of Her-2/neu amplification increases with progression to invasive carcinoma, there being no further increase in synchronous metastasis.
T18 2928-3107 DRI_Outcome denotes Our data suggest that amplification of Her-2/neu appears to be mainly involved in initiation of breast oncogenesis and that its role in progression of breast cancers is uncertain.